共 148 条
[1]
Baker KP(2003)Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator Arthritis Rheum. 48 3253-3265
[2]
Edwards BM(2020)Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a phase III study extension Rheumatology (Oxford). 59 281-291
[3]
Main SH(2020)Two-year, randomized, controlled trial of belimumab in lupus nephritis N Engl J Med 383 1117-1128
[4]
Choi GH(1994)Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data Kidney Int 45 544-550
[5]
Wager RE(2011)Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide Arthritis Care Res (Hoboken) 63 351-357
[6]
Halpern WG(2014)Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment J Rheumatol 41 688-697
[7]
Lappin PB(2018)ADDRESS II investigators. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study Arthritis Rheumatol. 70 266-276
[8]
Riccobene T(2020)Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study Rheumatology (Oxford). 59 2930-2938
[9]
Abramian D(2020)Targeting CD38 with daratumumab in refractory systemic lupus erythematosus N Engl J Med 383 1149-1155
[10]
Sekut L(1991)Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes Cell. 66 807-815